 PROSper is a prospective cohort study of 100 women 35-50 years of age with BRCA 12 mutations who have elected to either undergo risk reducing salpingo-oophorectomy RRSO or nonsurgical management. The investigators will compare the change in cardiovascular health, bone health, sexual function, quality of life, and menopausal symptoms over 3 years of follow-up between women who undergo RRSO baseline just prior to surgery and age-matched controls that do not undergo RRSO. 